Astria Therapeutics filings document the company's former Nasdaq-listed common stock, clinical-stage biopharmaceutical operations, material agreements, shareholder voting matters, and completed corporate-status changes. Its 8-K reports covered operating and financial results, the navenibart license agreement for Japan, merger-related agreements, security-holder voting results, and loan-guarantor obligations after the transaction closing.
The filing record also includes Form 25 removal of Astria common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting duties. Those filings record Astria's transition into a wholly owned subsidiary of BioCryst Pharmaceuticals and the end of separate public-company registration for its common stock.
Astria Therapeutics director Jonathan Violin reported automatic changes to his holdings following the company’s merger with BioCryst Pharmaceuticals. On January 23, 2026, Astria became a wholly owned subsidiary of BioCryst through a merger, and each Astria common share was converted into the right to receive 0.59 of a BioCryst common share plus $8.55 in cash, without interest and subject to taxes. Violin reported the disposition of 263,321 shares of Astria common stock in this transaction, leaving no common shares directly owned afterward. Several Astria stock options with exercise prices below $13.00 became fully vested at the merger’s effective time and were canceled in exchange for cash based on the difference between $13.00 and each option’s exercise price, while options with exercise prices at or above $13.00 were canceled with no payment.
Astria Therapeutics’ Chief Medical Officer, Christopher Morabito, reported the cash-out of stock options tied to the company’s acquisition by BioCryst Pharmaceuticals. On January 23, 2026, in connection with a merger where Axel Merger Sub, Inc. combined with Astria and Astria became a wholly owned subsidiary of BioCryst, two stock option awards covering 80,000 and 262,500 shares of common stock were disposed of.
According to the merger agreement, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable at the effective time of the merger and was then canceled in exchange for a cash payment equal to the number of underlying shares multiplied by the excess of $13.00 over the option’s exercise price, without interest. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported on this form.
Astria Therapeutics CEO Jill C. Milne reported the cancellation of her Astria equity holdings in connection with the company’s merger with BioCryst Pharmaceuticals. On January 23, 2026, she disposed of 4,377 shares of common stock, leaving her with no directly held Astria common shares.
On the same date, two blocks of Astria stock options were reported as disposed of: a 195,000-share option with a $6.51 exercise price and a 761,000-share option with a $6.41 exercise price, with zero options remaining after the transactions. Under the merger terms, each Astria share outstanding at the effective time (other than excluded shares) was converted into the right to receive 0.59 BioCryst common shares plus $8.55 in cash per share, subject to taxes. In-the-money Astria options became fully vested and were canceled in exchange for a cash payment based on a $13.00 reference price.